Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK | Zendy

S. Humphreys | Zendy; Sonia Pellissier | Zendy; Alison Jones | Zendy

Open Access

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Author(s) -

S. Humphreys,

Sonia Pellissier,

Alison Jones

Publication year - 2013

Publication title -

cancer management and research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.024

H-Index - 40

ISSN - 1179-1322

DOI - 10.2147/cmar.s44539

Subject(s) - aprepitant , nausea , medicine , vomiting , regimen , chemotherapy induced nausea and vomiting , breast cancer , oncology , chemotherapy , cancer , antiemetic

Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving chemotherapy. The objective of this study was to define, from the UK payer perspective, the cost-effectiveness of an antiemetic regimen using aprepitant, a selective neurokinin-1 receptor antagonist, for patients receiving chemotherapy for breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research